Skip to main content
  • 190 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Krell RD, Aharony D, Bruckner CK, Giles RE, Snyder DW (1990) Am Rev Resp Dis 141:978–987

    Article  PubMed  CAS  Google Scholar 

  2. Bernstein PR (1994) Drugs of the Future 19:217–220

    Google Scholar 

  3. Bruckner CK, Fedyna JS, Robertson JI (1990) J Pharm Exp Ther 252:77–85

    Google Scholar 

  4. Smith LJ, Geller S, Ebright L (1990) Am Rev Resp Dis 141:988–992

    Article  PubMed  CAS  Google Scholar 

  5. Smith LJ, Glass M, Minkwitz MC (1995) Am J Resp Crit Care Med 151:A378

    Article  Google Scholar 

  6. Dahlen B, Zetterstrom O, Bjorck T, Dahlen SE (1994) Eur Resp J 7:324–330

    Article  CAS  Google Scholar 

  7. Dahlen SE, Dahlen B, Eliasson E (1991) Adv Prost Thromb Leuk Res 21:461–464

    Google Scholar 

  8. Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT (1991) Lancet 337:690–694

    Article  PubMed  CAS  Google Scholar 

  9. Calhoun WJ, Lavins BJ, Glass M (1995) Am J Resp Crit Care Med 151:A42

    Google Scholar 

  10. Spector S, Miller CJ, Glass M (1995) Am J Resp Crit Care Med 151:A379

    Google Scholar 

  11. Townley R, Glass M, Minkwitz MC (1995) Am J Resp Crit Care Med 151:A380

    Google Scholar 

  12. Kemp JP, Glass M, Minkwitz MC (1995) J Allergy Clin Immunol 95:351 (abstract)

    Google Scholar 

  13. Bateman ED, Holgate ST, Binks SM (1995) Allergy 50:320 (Abstract P-0709)

    Google Scholar 

  14. Lockey RF, Lavins BJ, Snader L (1995) J Allergy Clin Immunol 95:350 (abstract)

    Article  Google Scholar 

  15. Hivid Roche®, Zalcitabin (ddC) Monographie (1995)

    Google Scholar 

  16. Eur Pat Appl, zit. nach CA (1985) 103:178579

    Google Scholar 

  17. Horwitz JP, Chua J, Noel M, Donatti JT (1967) J Org Chem 32:817–818

    Article  PubMed  CAS  Google Scholar 

  18. Lin TS, Chen MS, McLaren C, Gao YS, Ghazzouli I, Pru-soff WH (1987) J Med Chem 30:440–444

    Article  PubMed  CAS  Google Scholar 

  19. Beach JW, Kim O, Jeong LS, Nampalli S, Islam Q, Ahn SK, Babu JR, Chu CK (1992) J Org Chem 57:3887–3894

    Article  CAS  Google Scholar 

  20. Motawia MS, Pedersen EB (1990) Liebigs Ann Chem 599-602

    Google Scholar 

  21. Kaskar B, Marcovac A (1989) J Heterocyclic Chem 26:1531–1533

    Article  CAS  Google Scholar 

  22. Manchand PS, Belica PS, Holman MJ, Huang TN, Maehr H, Tarn SYK, Yang RT (1992) J Org Chem 57:3473–3478

    Article  CAS  Google Scholar 

  23. Huryn DM, Okabe M (1992) Chem Rev 92:1745–1768

    Article  CAS  Google Scholar 

  24. Whittington R, Brogden RN (1992) Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 44:656–683

    Article  PubMed  CAS  Google Scholar 

  25. Roche (1994) Fachinformation HIVID Roche®.

    Google Scholar 

  26. Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, Tsoukas C, Fallon MA, Self PL, Rubin M (1996) Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Ann Intern Med 125:161–172

    Article  PubMed  CAS  Google Scholar 

  27. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 334:1011–1017

    Article  PubMed  CAS  Google Scholar 

  28. Delta Coordinating Committee (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348:283–291

    Article  Google Scholar 

  29. Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame FT, Remick SC, Salgo MP, Lin AH, Nauss-Ka-rol C (1993) Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 118:762–769

    Article  PubMed  CAS  Google Scholar 

  30. Graham NM, Hoover DR, Park LP, Stein DS, Phair JP, Mellors JW, Detels R, Saah AJ (1996) Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 124:1031–1038

    Article  PubMed  CAS  Google Scholar 

  31. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pet-tinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D (1996) Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 335:1099–1106

    Article  PubMed  CAS  Google Scholar 

  32. Skowron G, Bozzette SA, Lim L, Pettinelli CB, Schaumburg HH, Arezzo J, Fischl MA, Powderly WG, Gocke DJ, Richman DD (1993) Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 118:321–330

    Article  PubMed  CAS  Google Scholar 

  33. Drugs Fut (1988) 13(4):302-304

    Google Scholar 

  34. Fujimoto Y, Yamabe S (Nippon Chemiphar Co., Ltd.) DE 2,941,869

    Google Scholar 

  35. Drugs Tod (1994) 30(6):515-525

    Google Scholar 

  36. Tsurumi K, Kyuki K, Niwa M, Kokuba S et al. (1986) Arz-neim Forsch/Drug Res 36(11), Nr. 12:1796–1800

    CAS  Google Scholar 

  37. Yoshioka M, Yamamoto T, Okai K (1991) Iyakuhin Ken-kyu 22(5):836–844, zit. nach CA (1992) 116:67029

    CAS  Google Scholar 

  38. Oshima J, Horai Y, Ishizaki T (1987) J Chromatogr 414(2):381–388

    PubMed  CAS  Google Scholar 

  39. Yamamoto M, Masaki M, Nohira H (1990) Chiralty 2:280–283

    Article  CAS  Google Scholar 

  40. Johnston CI (1990) Biochemistry and pharmacology of the renin-angiostensin system. Drugs 39:21–31

    Article  PubMed  CAS  Google Scholar 

  41. Menard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD Dose dependent effects of the renin inhibitor zankiren HCL after a single oral doses in mildly sodium-depleted normotensive subjects. Circulation 91:330-338

    Google Scholar 

  42. Mar31, S. 102

    Google Scholar 

  43. Boger RS, Glassman HN, Thys R (1993) Absorption and blood pressure response to the new orally active renin inhibitor, A-72517, in hypertensive patients. Am J Hypertension 6:103A

    Google Scholar 

  44. Williams PD, Calligaro DO, Colbert WE, Helton DR, Shetler T, Turk JA, Jordan WH (1991) General pharmacology of a new potent 5-hydroxytryptamine antagonist. Arzneimittelforsch 41:189–195

    PubMed  CAS  Google Scholar 

  45. Schwartz SM, Goldberg MG, Gidda JS, Cerimele BJ (1994) Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. J Clin Pharmacol 34:250–254

    Article  PubMed  CAS  Google Scholar 

  46. Cohen ML, Bloomquist W, Gidda JS, Lacefield W (1990) LY277359 maleate: a potent and selective 5-HT3 recpetor antagonist without gastroprokinetic activity. J Pharmacol Exp Ther 254:350–355

    PubMed  CAS  Google Scholar 

  47. Chappell AS, Bay JM, Botzum GD, Cohen ML (1994) Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial or acute migraine. Neuropharmacology 33:509–513

    Article  PubMed  CAS  Google Scholar 

  48. Franz PM, Mattiuz EL, Hatcher BL, deSante KA, Breau AP, Occolowitz JL, Dorman DE, Schmid CR, Goldberg MJ, Rubin A (1993) Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans. Drug Metab Dispos 21:249–254

    PubMed  CAS  Google Scholar 

  49. Robertson DW, Lacefield WB, Blomquist W, Pfeifer W, Simon RL, Cohen ML (1992) J Med Chem 35:310–319

    Article  PubMed  CAS  Google Scholar 

  50. Drugs Fut (1994) 19:850-853

    Google Scholar 

  51. Drugs Fut (1989) 14(1):26-28

    Google Scholar 

  52. Hashimoto M, Oku T, Ito Y, Namiki T et al. (Fujisawa Pharm. Co., Ltd) AU 8663589, EP 218999, JP 87096476, US 4734419

    Google Scholar 

  53. Tanaka Y, Shimojyo H, Hata T, Hashimoto M et al. (1994) Xenobiotica 24(5):461–471

    Article  PubMed  CAS  Google Scholar 

  54. Kanamaru M (1993) J Clin Pharmacol 33(11):1122

    Article  PubMed  CAS  Google Scholar 

  55. Drugs Fut (1993) 18:616-618

    Google Scholar 

  56. Alvarez FJ, Slade RT (1992) Pharm Res 9:1465–1473, zit. nach CA (1993) 118:219607

    Article  PubMed  CAS  Google Scholar 

  57. Stewart AO, Brooks DW (1992) J Org Chem 57:5020–5023

    Article  CAS  Google Scholar 

  58. Bell RL, Lanni C, Malo PE, Stewart AO, Brooks DW, Rubin P, Carter GWI (1993) Ann NY Acad Sci 696:205–215

    Article  PubMed  CAS  Google Scholar 

  59. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB, Brooks DW (1991) J Pharmacol Exp Ther 256:929–937

    PubMed  CAS  Google Scholar 

  60. Israel E, Rubin P, Kemp JP (1993) Ann Intern Med 119:1059–1061

    Article  PubMed  CAS  Google Scholar 

  61. Malo PE, Bell RL, Shaughnessy TK, Bouska J, Summers JB, Brooks DW, Carter GW (1993) Pulm Pharmacol 7:73–79

    Article  Google Scholar 

  62. Abraham WM, Ahmed A, Cortes A, Sielczak M, Hinz W, Bouska J, Lanni C, Bell R (1992) Eur J Pharmacol 217:119–126

    Article  PubMed  CAS  Google Scholar 

  63. Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi AP (1993) Agents Actions 39:150–156

    Article  PubMed  CAS  Google Scholar 

  64. Laursen LS, Lauritsen K, Bukhave K (1994) Eur J Ga-stroenterol Hepatol 6:209 (abstract)

    Article  Google Scholar 

  65. Hawkey C, Gassull M, Lauritsen K, Martin F, O’Morain C, Rask-Madsen J, Wright J, Dube L, Rountree L, Brout-man L (1994) Gastroenterology 106 (Suppl):A697 (abstract)

    Google Scholar 

  66. Israel E, Drazen J, Pearlman H, Cohn J, Rubin PA (1992) Allergy Clin Immunol 89:236–241

    Google Scholar 

  67. Wenzel S, Colin J, Trudeau J, Wilson W, Martin R, We-scott J (1994) Allergy Clin Immunol News (Suppl 2):Abstr. 302

    Google Scholar 

  68. Knapp HR (1990) New Engl J Med 323:1745–1748

    Article  PubMed  CAS  Google Scholar 

  69. Wong SL, Awni WM, Cavanaugh JH, el-Shourbagy T, Locke CS, Dube LM (1995) Clin Pharmacokinetics 29(Suppl 2):9–21

    Article  CAS  Google Scholar 

  70. Awni WM, Braeckmann RA, Granneman GR, Wirr G, Dube LM (1995) Clin Pharmacokinetics 29(Suppl 2):22–33

    Article  CAS  Google Scholar 

  71. Books DW, Bell RL, Carter GW, Dube LM, Rubin PD (1993) Drugs of the Future 18:616–618

    Google Scholar 

  72. Braeckman RA, Hui J, Cavanaugh JH, Rubin PD (1993) Clin Pharmacol Ther 53:P11–44 (abstract)

    Google Scholar 

  73. Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM (1995) Clin Pharmacokinet 29 (Suppl 2):77–83

    Article  PubMed  CAS  Google Scholar 

  74. Awni WM, Braeckman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR, Dube LM (1995) Clin Phar-macokinet 29 (Suppl 2): 112–124

    Article  CAS  Google Scholar 

  75. bg Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag: Bd. 3

    Google Scholar 

  76. Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag: Bd. 3

    Google Scholar 

  77. Voisin H (1969) Materia medica des hom. Praktikers, Haug-Verlag Heidelberg: S. 1226

    Google Scholar 

  78. Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 3

    Google Scholar 

  79. DHU, Karlsruhe (1994) S: 310-311

    Google Scholar 

  80. Voisin H (1969) Materia rnedica des hom. Praktikers, Haug-Verlag: S. 1227

    Google Scholar 

  81. Boericke W (1994) Hom. Mittel und ihre Wirkungen, wis-senschaftl. Autorenverlag Leer/Ostfriesland: S.529-530

    Google Scholar 

  82. Drugs of the Future (1985) 10:281-285

    Google Scholar 

  83. Schneider MR, von Angerer E, Hohn W, Sinowatz F (1987) Antitumor activity of antiestrogenic phenylidoles on experimental prostate tumors. Eur J Cancer Clin Oncol 23(7):1005–1015

    Article  PubMed  CAS  Google Scholar 

  84. Robinson SP, Koch R, Jordan VC (1988) In vitro estroge-nic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo. Cancer-Res 48(4):784–787

    PubMed  CAS  Google Scholar 

  85. Stein RC, Dowsett M, Cunningham DC, Davenport J, Ford HT, Gazet JC, von Angerer E, Coombes RC (1990) Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. Br J Cancer 61(3):451–453

    Article  PubMed  CAS  Google Scholar 

  86. Bulbena O, Esplugues JV, Escolar G, Gil L, Navarro C, Esplugues (1990) J Pharm Pharmacol 42:252–256

    Article  PubMed  CAS  Google Scholar 

  87. Escolar G, Navarro C, Sendros S, Bulbena O (1987) Arch Int Pharmacodyn Ther 290:128–137

    PubMed  CAS  Google Scholar 

  88. Bulbena O, Esplugues JV, Escolar G, Navarro C, Esplugues J (1989) Prostaglandins Leukotrienes Essent Fatty Acids 36:119–123

    Article  CAS  Google Scholar 

  89. Navarro C, Escolar G, Banos JE, Casanovas LI, Bulbena O (1988) Prostaglandins Leukotrienes Essent Fatty Acids 33:75–80

    Article  CAS  Google Scholar 

  90. Jimenez E, Bosch F, Galmes JL, Banos JE (1992) Digestion 51:18–26

    Article  PubMed  CAS  Google Scholar 

  91. Mar 30, S. 1216

    Google Scholar 

  92. Maeda H (1988) Drugs Fut 13:841–842

    Google Scholar 

  93. Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M (1984) J Prot Chem 3:181–193

    Article  CAS  Google Scholar 

  94. Maeda H, Ueda M, Morinaga T, Matsumoto T (1985) J Med Chem 28:455–461

    Article  PubMed  CAS  Google Scholar 

  95. Oda T, Maeda H (1987) Cancer Res 47:3206–3211; zit. nach Lit. 1

    PubMed  CAS  Google Scholar 

  96. Oda T, Sato F, Maeda H (1987) J Nat T Cancer Inst 79:1205–1211, zit. nach Lit. 1

    CAS  Google Scholar 

  97. Weber K, Osborn M (1969) J Biol Chem 244:4406

    PubMed  CAS  Google Scholar 

  98. Tananka S, Numasaki Y, Maeda H (1991) Action mechanisms of zinostatin stimalamer (YM881). Gan to Kagaku Ryoho 18(13):2295–2300

    Google Scholar 

  99. Toge T, Jinushi K, Sawamura A, Matsuki K (1991) Study on the intra-tumor tissue concentration of zinostatin stimalamer in the liver following intra-arterial injection of zinostatin stimalamer (YM881) suspension. Gan to Kagaku Ryoho 18(10):1677–1680

    PubMed  CAS  Google Scholar 

  100. Taguchi T, Saito T, Ota J, Nakao I, Ohashi K, Nakamura H, Konno T (1991) Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Research Group for Intra-arterial Injection therapy with YM881. Gan To Kagaku Ryoho 18(10):1665–1675

    PubMed  CAS  Google Scholar 

  101. Saito T, Nakao I, Wakui A, Kurihara M, Niitani H, Konno T, Tsukagoshi S, Maeda H (1991) Phase I clinical study of zinostatin stimalamer (YM881) by intravenous injection. Gan To Kagaku Ryoho 18(8):1311–1318

    PubMed  CAS  Google Scholar 

  102. Saito T, Nakao I, Wakui A, Niitani H, Kurihara M, Konno T, Tsukagoshi S, Maeda H (1991) Early phase II study of YM881 (zinostatin stimalamer) by intravenous injection, research group for intravenous YM881: Gan To Kagaku Ryoho 18(8):1319–1323

    PubMed  CAS  Google Scholar 

  103. Krapcho J, Turk C, Cushman DW, Powell JR, DeForrest JM, Spitzmiller IR, Karanewsky DS, Duggan M, Rovnvak G, Schwartz J, Natarajan S, Godfrey JD, Ryono DE, Neubeck R, Atwal KS, Petrillo EW (1988) J Med Chem 31:1148–1160

    Article  PubMed  CAS  Google Scholar 

  104. US-Patent 4316906

    Google Scholar 

  105. Lacouriere Y, Provencher P (1989) Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressure in mild to moderate essential hypertension. Br J Clin Pharmacol 27:371–376

    Article  Google Scholar 

  106. Salvetti A (1990) Newer ACE inhibitors. A look at the future. Drugs 40:800–828

    Article  PubMed  CAS  Google Scholar 

  107. Ambrosioni E, Borghi C, Magnani B (1995) The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332:80–85

    Article  PubMed  CAS  Google Scholar 

  108. Drugs Fut (1991) 12:787-780

    Google Scholar 

  109. Allen J, Tizot A (1986) J of Labelled Compounds and Ra-diopharmaceuticals XXIII:393–400

    Article  Google Scholar 

  110. Allen J, Parent G, Tizot A (1986) J of Labelled Compounds and Radiopharmaceuticals XXIIL:807–813

    Article  Google Scholar 

  111. Ahrens B, Schütz H, Seno H, Weiler G (1994) Arzneim Forsch 44:799–802

    CAS  Google Scholar 

  112. Guinebault P, Dubruc C, Hermann P, Thenot JP (1986) J Chromatogr 383:206–211

    Article  PubMed  CAS  Google Scholar 

  113. Hempel G, Blaschke G (1996) J Chromatogr B 675:131–137

    Article  CAS  Google Scholar 

  114. Arbilla S, Allen J, Wick A, Langer SZ (1986) High affinity 3H-Zolpidem binding in the rat brain: an imidazopyridine with agonist properties at central benzodiazepine receptors. Eur J Pharmacol 130:257–263

    Article  PubMed  CAS  Google Scholar 

  115. Berlin I, Warot D, Hergueta T, Moliniert P, Bagot C, Puech AJ (1993) Comparison of the effects of zolpidem and tria-zolam on memory functions, psychomotor, and postural sway in healthy subjects. J Clin Psychopharmacol 13:100–106

    Article  PubMed  CAS  Google Scholar 

  116. Colle M, Rosenzweig P, Bianchetti G, Fuseau E, Ruffie A, Ruedas E, Morselli PL (1991) Nocturnal profile of growth hormone secretion during sleep induced by zolpidem: a double-blind study in young adults and children. Hormone Res 35:30–34

    Article  PubMed  CAS  Google Scholar 

  117. Debailleul G, Khalil FA, Lheureux P (1991) HPLC quantification of zolpidem and prothipendyl in a voluntary intoxication. J Anal Toxicol 15:35–37

    Article  PubMed  CAS  Google Scholar 

  118. Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF (1988) Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a pheno-thiazine neuroleptic. Psychopharmacol 96:163–166

    Google Scholar 

  119. Durand A, Thenot JP, Bianchetti G, Morselli PL (1992) Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metabol Rev 24:239–266

    Article  CAS  Google Scholar 

  120. Fillastre JP, Geffroy-Josse S, Etienne I, Dhib M, Rosenzweig P, Danjou P, Dubruc C, Bianchetti G (1993) Phar-macokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients. Fundament Clin Pharmacol 7:1–9

    Article  CAS  Google Scholar 

  121. Gamier R, Guerault E, Muzard D, Azoyan P, Chaumet-Riffaud AE, Efthymiou ML (1994) Acute zolpidem poisoning-analysis of 344 cases. J Toxicol Clin Toxicol 32:391–404

    Article  Google Scholar 

  122. Hoehns JD, Perry PJ (1993) Zolpidem: a nonbenzodiaze-pine hypnotic for treatment of insomnia. Clin Pharm 12:814–728

    PubMed  CAS  Google Scholar 

  123. Hulhoven R, Desager JP, Harvengt C, Hermann P, Guillet P, Thiercelin JF (1988) Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Res 8:471–476

    PubMed  CAS  Google Scholar 

  124. Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW (1992) Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiat 53 Suppl: 19–34; discussion 32-33

    Google Scholar 

  125. Langtry HD, Benfield P (1990) Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291–313

    Article  PubMed  CAS  Google Scholar 

  126. Mastain B, Vaiva G, Guerouau D, Pommery J, Thomas P (1995) Effet favorable du zolpidem sur un etat catatoni-que. Rev Neurol 151:52–56

    PubMed  CAS  Google Scholar 

  127. Monti JM (1989) Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 36:461–466

    Article  PubMed  CAS  Google Scholar 

  128. Morselli PL (1993) Zolpidem side-effects (letter, comment). Lancet 342:868–869

    PubMed  CAS  Google Scholar 

  129. Patat A, Trocherie S, Thebault JJ, Rosenzweig P, Dubruc C, Bianchetti G, Court La, Morselli PL (1994) EEG profile of intravenous zoplidem in healthy volunteers. Psychopharmacol 114:138–146

    Article  CAS  Google Scholar 

  130. Pons G, Francoual C, Guillet P, Moran C, Hermann P, Bianchetti G, Thiercelin JF, Thenot JP, Olive G (1989) Zolpidem excretion in breast milk. Europ J Clin Pharmacol 37:245–248

    Article  CAS  Google Scholar 

  131. Praplan-Pahund J, Forster A, Gamulin Z, Tassonyi E, Sauvanet JP (1990) Preoperative sedation before regional anaesthesia: comparison between zolpidem, midazolam and placebo. Brit J Anaesth 64:670–674

    Article  Google Scholar 

  132. Wilkinson CJ (1995) The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psycho-motor function. J Clin Psychiat 56:309–318

    CAS  Google Scholar 

  133. Beyer-Mears A, Mistry K, Diecke FP et al. (1996) Pharmacology 52:292–302

    Article  PubMed  CAS  Google Scholar 

  134. Inskeep PB, Ronfeld RA, Peterson MJ et al. (1994) J Clin Pharmacol 34:760–66

    Article  PubMed  CAS  Google Scholar 

  135. Ramasamy R, Oates PJ, Schaefer S (1997) Diabetes 46:292–300

    Article  PubMed  CAS  Google Scholar 

  136. Tesfamariam B, Palacino JJ, Weisbrod RM et al. (1993) J Cardiovasc Pharmacol 21:205–11

    Article  PubMed  CAS  Google Scholar 

  137. Drugs Fut (1995) 20(1):33-36

    Google Scholar 

  138. Mylari BL, Larson ER, Beyer TA, Zembrowski WJ et al. (1991) J Med Chem 34(1):108–122, zit. nach CA (1991) 114:42696

    Article  PubMed  CAS  Google Scholar 

  139. Mylari BL, Zembrowski WJ (1991) J Label Compound Radiopharm 29(2):143–148

    Article  CAS  Google Scholar 

  140. Mylari BL, Zembrowski WJ (Pfizer, Inc.) EP 295051, zit. nach CA (1989) 111:134180

    Google Scholar 

  141. Mylari BL, Larson ER, Zembrowski WJ (Pfizer, Inc.) EP 222576 (JP 87114988, US 4939140), zit. nach CA (1987) 107:176055.

    Google Scholar 

  142. Inskeep BP, Ronfeld RA, Peterson MJ, Gerber N (1994) J Clin Pharmacol 34(7):760–766

    Article  PubMed  CAS  Google Scholar 

  143. Drugs Fut (1979) IV(10):758-759

    Google Scholar 

  144. (1996) Japan Pharmaceutical Reference, 4. Auflage, S. 273-276

    Google Scholar 

  145. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, van Gompel P, Lesage AS, Loore K, Leysen JL (1996) Risperidone compared with new and reference antipsy-chotic drugs: in vitro and in vivo receptor binding Psych-pharmacology 124:57–73

    CAS  Google Scholar 

  146. Miiller-Spahn F, Dieterle D, Ackenheil M (1991) Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms. Fortschr Neurol Psychiat 51:30–35

    Article  Google Scholar 

  147. Fleischhacker WW, Hummer M (1997) Drug treatment of schizophrenia in the 1990s. Drugs 53:915–929

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

von Bruchhausen, F. et al. (1999). Z. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-58388-9_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63569-4

  • Online ISBN: 978-3-642-58388-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics